Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion's Opsumit Shows MERIT In CTEPH

Executive Summary

The Switzerland-based biotech Actelion is bullish about new indications and labeling updates for its marketed pulmonary arterial hypertension product macitentan, including in CTEPH, and has also unveiled a promising Phase II candidate for resistant hypertension.

You may also be interested in...



Keeping Track: FDA's Review Actions Carry On During Shutdown

The latest drug development news and highlights from our US FDA Performance Tracker.

J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure

Johnson & Johnson is expected to keep pursuing Actelion despite news the target's pulmonary arterial hypertension drug macitentan missed a primary endpoint in a Phase III study of patients with PAH due to Eisenmenger Syndrome.

Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?

Reported M&A talks between Sanofi and Actelion will likely stand or fall on the former's willingness to overpay and the target's demanded price for surrendering its independence.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel